Tisotumab vedotin - Genmab/Seattle Genetics

Drug Profile

Tisotumab vedotin - Genmab/Seattle Genetics

Alternative Names: Humax TF ADC; HuMax-TF; HuMax-TF-ADC; TF-011-MMAE; Tisotumab vedotin

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genmab
  • Developer Genmab; Seattle Genetics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bladder cancer; Cervical cancer; Endometrial cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 12 Jun 2018 Phase-II clinical trials in Cervical cancer (Recurrent, Metastatic disease, Second-line therapy or greater) in Spain (IV) (Seattle Genetics pipeline, June 2018) (NCT03438396)
  • 12 Jun 2018 Seattle Genetics plans the phase II innovaTV 207 trial in Solid tumours (Seattle Genetics pipeline, June 2018)
  • 01 Jun 2018 Phase-II clinical trials in Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in Germany, USA, Denmark (IV) (EudraCT2017-003413-25) (NCT03438396)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top